Teva delivered its 10th consecutive quarter of year-over-year revenue growth in Q2 2025, with total revenues reaching $4.2 billion. The company's innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, significantly contributed to this growth, offsetting declines in generic products and COPAXONE. Teva also increased its 2025 revenue outlook for key innovative products and EPS, while reaffirming other financial guidance components.
Teva achieved $4.2 billion in revenues in Q2 2025, marking its 10th consecutive quarter of year-over-year growth.
The innovative portfolio, particularly AUSTEDO, AJOVY, and UZEDY, was the primary driver of revenue growth, with AUSTEDO global revenues at $498 million (+19% LC), AJOVY at $155 million (+31% LC), and UZEDY at $54 million (+120%).
GAAP diluted EPS was $0.24, and non-GAAP diluted EPS increased by 9% year-over-year to $0.66.
Free cash flow significantly increased by 47% year-over-year to $476 million in Q2 2025.
Teva has increased its 2025 revenue outlook for key innovative products (AUSTEDO, AJOVY, UZEDY) and non-GAAP diluted EPS, while reaffirming its overall revenue, non-GAAP operating income, Adjusted EBITDA, and free cash flow guidance for the full year 2025.
Visualization of income flow from segment revenue to net income